

**Supplemental Material S1.** Characteristics of included studies by year.

Author	Year	Design	Study Sample (N)	Case Sample (n)		
				pSS	sSS	SS <sup>a</sup>
Mandel & Baurmash	1976	Case-control	24	—	—	12
Benedek-Spät et al.	1980	Case-control	57	—	—	28
Stuchell et al.	1984	Case-control	27	—	—	15
Markusse et al.	1993	Case-control	122	39	—	—
Van Der Geest et al.	1993	Case-control	59	29	—	—
Tishler et al.	1996	Case-control	46	18	—	—
van der Reijden et al.	1996	Case-control	60	33	10	—
Tishler et al.	1998	Case-control	65	36	—	—
Pedersen et al.	1999	Case-control	43	16	—	—
Zipp et al.	1999	Case-control	46	—	—	24
Dawson et al.	2001	Case-control	134	67	67	—
Kalk et al.	2001	Case-control	100	33	25	—
Moody et al.	2001	Case-control	40	—	—	20
Haga	2002	Case series	72	72	—	—
Kalk et al.	2002	Case-control	100	33	25	—
Sfriso et al.	2003	Case-control	50	30	—	—
Vissink et al.	2003	Cohort study	80	32	25	—
Asatsuma et al.	2004	Case-control	58	32	—	—
Bertorello et al.	2004	Case-control	40	10	4	—
Eliasson et al.	2005	Case-control	40	10	—	—
Hammi et al.	2005	Case-control	60	20	20	—
Pedersen et al.	2005	Case-control	40	20	—	—
Márton et al.	2006	Case-control	92	49	—	—
Deming et al.	2007	Case-control	40	17	3	—
Pijpe et al.	2007	Cohort study	60	32	28	—
Bostrom et al.	2008	Case-control	69	37	—	—

<sup>a</sup>Type unspecified.

Author	Year	Design	Study Sample (N)	Case Sample (n)		
				pSS	sSS	SS <sup>a</sup>
Busamia et al.	2010	Case-control	73	15	17	—
Cho et al.	2010	Case-control	140	25	9	34
Higashi et al.	2010	Case-control	23	10	—	—
Hu et al.	2010	Case-control	102	34	—	—
Lee et al.	2010	Case-control	85	30	—	—
Baldini et al.	2011	Case-control	105	40	—	—
Hu et al.	2011	Case-control	40	14	—	—
Kang et al.	2011	Case-control	85	30	—	—
He et al.	2012	Case-control	240	100	—	—
Miller et al.	2012	Case-control	41	17	—	—
Asashima et al.	2013	Case-control	250	71	50	—
Azuma et al.	2014	Case-control	63	27	13	—
Azuma et al.	2015	Case-control	37	14	9	—
Hernandez-Molina et al.	2015	Case-control	60	30	—	—
Kageyama et al.	2015	Case-control	33	12	—	—
Ohyama et al.	2015	Case-control	178	—	—	90
Billings et al.	2016	Case-control	2046	—	—	701
Kabeerdoss et al.	2016	Case-control	74	43	—	—
Wang et al.	2016	Case-control	320	80	—	—
Martini et al.	2017	Case-control	60	40	—	—
Rusthen et al.	2017	Case-control	64	31	—	—
Blochowiak et al.	2018	Case-control	49	16	18	—
Mandal et al.	2018	Case-control	87	45	—	—
Aqrawi et al.	2019	Case-control	35	10	—	—
Hung et al.	2019	Case-control	238	138	—	—
Jin et al.	2019	Case-control	296	137	32	—
Lee et al.	2019	Case-control	316	170	—	—
Singh et al.	2019	Case-control	137	58	—	—
Tvarijonaviciute et al.	2019	Case-control	49	—	—	17

<sup>a</sup>Type unspecified.

## References

- Aqrawi, L. A., Galtung, H. K., Guerreiro, E.M., Øvstebø, R., Thiede, B., Utheim, T. P., Chen, X., Utheim, Ø. A., Palm, Ø., Skarstein, K., & Jensen, J. L. (2019). Proteomic and histopathological characterisation of sicca subjects and primary Sjögren’s syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers. *Arthritis Research and Therapy*, 21(181). <https://doi.org/10.1186/s13075-019-1961-4>
- Asashima, H., Inokuma, S., Onoda, M., & Oritsu, M. (2013). Cut-off levels of salivary beta2-microglobulin and sodium differentiating patients with Sjögren’s syndrome from those without it and healthy controls. *Clinical and Experimental Rheumatology*, 31(5), 699–703.
- Asatsuma, M., Ito, S., Watanabe, M., Takeishi, H., Nomura, S., Wada, Y., Nakano, M., Gejyo, F., & Igarashi, A. (2004). Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren’s syndrome. *Clinica Chimica Acta*, 345(1–2), 99–104. <https://doi.org/10.1016/j.cccn.2004.03.006>
- Azuma, N., Katada, Y., Kitano, S., Sekiguchi, M., Kitano, M., Nishioka, A., Hashimoto, N., Matsui, K., Iwasaki, T., & Sano, H. (2014). Correlation between salivary epidermal growth factor levels and refractory intraoral manifestations in patients with Sjögren’s syndrome. *Modern Rheumatology*, 24(4), 626–632. <https://doi.org/10.3109/14397595.2013.850766>
- Azuma, N., Katada, Y., Kitano, S., Sekiguchi, M., Kitano, M., Nishioka, A., Hashimoto, N., Matsui, K., Iwasaki, T., & Sano, H. (2015). Rapid decrease in salivary epidermal growth factor levels in patients with Sjögren’s syndrome: A 3-year follow-up study. *Modern Rheumatology*, 25(6), 876–882. <https://doi.org/10.3109/14397595.2015.1034941>
- Baldini, C., Giusti, L., Ciregia, F., Da Valle, Y., Giacomelli, C., Donadio, E., Semissi, F., Bazzichi, L., Giannaccini, G., Bombardieri, S., & Lucacchini, A. (2011). Proteomic analysis of saliva: A unique tool to distinguish primary Sjögren’s syndrome from secondary Sjögren’s syndrome and other sicca syndromes. *Arthritis Research & Therapy*, 13(6), R194. <https://doi.org/10.1186/ar3523>
- Benedek-Spät, E., Puskás, M., & Kajki, J. (1980). Electrophoretic protein pattern of human parotid saliva in Sjögren’s syndrome and sialosis. *Acta Oto-Laryngologica*, 90(1–6), 275–282. <https://doi.org/10.3109/00016488009131726>
- Bertorello, R., Cordone, M. P., Contini, P., Rossi, P., Indiveri, F., Puppo, F., & Cordone, G. (2004). Increased levels of interleukin-10 in saliva of Sjögren’s syndrome patients. Correlation with disease activity. *Clinical and Experimental Medicine*, 4(3), 148–151. <https://doi.org/10.1007/s10238-004-0049-9>
- Billings, M., Dye, B. A., Iafolla, T., Baer, A. N., Grisius, M., & Alevizos, I. (2016). Significance and implications of patient-reported xerostomia in Sjögren’s syndrome: Findings from the National Institutes of Health Cohort. *EBioMedicine*, 12, 270–279. <https://doi.org/10.1016/j.ebiom.2016.09.005>
- Blochowiak, K. J., Trzybulska, D., Olewicz-Gawlik, A., Sikora, J. J., Nowak-Gabryel, M., Kocięcki, J., Witmanowski, H., & Sokalski, J. (2018). Levels of EGF and VEGF in patients with primary and secondary Sjögren’s syndrome. *Advances in Clinical and Experimental Medicine*, 27(4), 455–461. <https://doi.org/10.17219/acem/70800>
- Boström, E., D’Elia, H. F., Dahlgren, U. L. F., Simark-Mattsson, C., Hasséus, B., Carlsten, H., Tarkowski, A., & Bokarewa, M. (2008). Salivary resistin reflects local inflammation in Sjögren’s syndrome. *Journal of Rheumatology*, 35(10), 2005–2011.
- Busamia, B., Gonzales-Moles, M. A., Mazzeo, M., Linares, J., Demarchi, M., Gobbi, C., Albiero, E., & Finkelberg, A. (2010). Assessing the determination of salivary electrolytes and anti-Ro and anti-La antibodies for the diagnosis of Sjögren’s syndrome (SS). *Medicina Oral, Patología Oral y Cirugía Bucal*, 15(3), e437–e440. <https://doi.org/10.4317/medoral.15.e437>
- Cho, M.-A., Ko, J.-Y., Kim, Y.-K., & Kho, H.-S. (2010). Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. *Journal of Oral Rehabilitation*, 37(3), 185–193. <https://doi.org/10.1111/j.1365-2842.2009.02037.x>
- Dawson, L. J., Holt, D. J., Higham, S. M., Longman, L. P., & Field, E. A. (2001). A comparison of salivary gland hypofunction in primary and secondary Sjögren’s syndrome. *Oral Diseases*, 7(1), 28–30. <https://doi.org/10.1034/j.1601-0825.2001.0070106.x>
- Deming, F. P., Al-Hashimi, I., Haghghat, N., Hallmon, W. W., Kerns, D. G., Abraham, C., & Rivera-Hidalgo, F. (2007). Comparison of salivary calmodulin binding proteins in Sjögren’s syndrome and healthy individuals. *Journal of Oral Pathology & Medicine*, 36(3), 132–135. <https://doi.org/10.1111/j.1600-0714.2006.00494.x>
- Eliasson, L., Almståhl, A., Lingström, P., Wikström, M., & Carlén, A. (2005). Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjögren’s syndrome and radiation therapy. *Archives of Oral Biology*, 50(3), 293–299. <https://doi.org/10.1016/j.archoralbio.2004.08.009>
- Haga, H. J. (2002). Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren’s syndrome. *The Journal of Rheumatology*, 29(2), 305–308.
- Hammi, A. R., Al-Hashimi, I. H., Nunn, M. E., & Zipp, M. (2005). Assessment of SS-A and SS-B in parotid saliva of patients with Sjögren’s syndrome. *Journal of Oral Pathology & Medicine*, 34(4), 198–203. <https://doi.org/10.1111/j.1600-0714.2004.00301.x>
- He, J., Qiang, L., Ding, Y., Wei, P., Li, Y. N., Hua, H., & Li, Z. G. (2012). The role of muscarinic acetylcholine receptor type 3 polypeptide (M3RP205-220) antibody in the saliva of patients with primary Sjögren’s syndrome. *Clinical & Experimental Rheumatology*, 30(3), 322–326.
- Hernandez-Molina, G., Burkhardt, A. M., Lima, G., Zlotnik, A., Betanzos, J. L., Bahena, S., & Llorente, L. (2015). Absence of salivary CCL28 in primary Sjögren’s syndrome. *Rheumatology International*, 35(8), 1431–1434. <https://doi.org/10.1007/s00296-014-3210-0>
- Higashi, K., Yoshida, M., Igarashi, A., Ito, K., Wada, Y., Murakami, S., Kobayashi, D., Nakano, M., Sohda, M., Nakajima, T., Narita, I., Toida, T., Kashiwagi, K., & Igarashi, K. (2010). Intense correlation between protein-conjugated acrolein and primary Sjögren’s syndrome. *Clinica Chimica Acta*, 411(5–6), 359–363. <https://doi.org/10.1016/j.cca.2009.11.032>
- Hu, S., Gao, K., Pollard, R., Arellano-Garcia, M., Zhou, H., Zhang, L., Elashoff, D., Kallenberg, C. G., Vissink, A., & Wong, D. T. (2010). Preclinical validation of salivary biomarkers for primary Sjögren’s syndrome. *Arthritis Care & Research*, 62(11), 1633–1638. <https://doi.org/10.1002/acr.20289>
- Hu, S., Vissink, A., Arellano, M., Roozendaal, C., Zhou, H., Kallenberg, C. G. M., & Wong, D. T. (2011). Identification of autoantibody biomarkers for primary Sjögren’s syndrome using protein microarrays. *Proteomics*, 11(8), 1499–1507. <https://doi.org/10.1002/pmic.201000206>

- Hung, Y.-H., Lee, Y.-H., Chen, P.-P., Lin, Y.-Z., Lin, C.-H., & Yen, J.-H. (2019). Role of salivary immune parameters in patients with primary Sjögren’s syndrome. *Annals of Laboratory Medicine*, 39(1), 76–80. <https://doi.org/10.3343/alm.2019.39.1.76>
- Jin, Y., Li, J., Chen, J., Shao, M., Zhang, R., Liang, Y., Zhang, X., Zhang, Q., Li, F., Cheng, Y., Sun, X., He, J., & Li, Z. (2019). Tissue-specific autoantibodies improve diagnosis of primary Sjögren’s syndrome in the early stage and indicate localized salivary injury. *Journal of Immunology Research*, 2019, 3642937. <https://doi.org/10.1155/2019/3642937>
- Kabeerdoss, J., Sandhya, P., Mandal, S. K., Gowri, M., & Danda, D. (2016). High salivary soluble L-selectin and interleukin-7 levels in Asian Indian patients with primary Sjögren’s syndrome. *Clinical Rheumatology*, 35(12), 3063–3067. <https://doi.org/10.1007/s10067-016-3406-7>
- Kageyama, G., Saegusa, J., Irino, Y., Tanaka, S., Tsuda, K., Takahashi, S., Sendo, S., & Morinobu, A. (2015). Metabolomics analysis of saliva from patients with primary Sjögren’s syndrome. *Clinical & Experimental Immunology*, 182(2), 149–153. <https://doi.org/10.1111/cei.12683>
- Kang, E. H., Lee, Y. J., Hyon, J. Y., Yun, P. Y., & Song, Y. W. (2011). Salivary cytokine profiles in primary Sjögren’s syndrome differ from those in non-Sjögren sicca in terms of TNFalpha levels and Th-1/Th-2 ratios. *Clinical and Experimental Rheumatology*, 29(6), 970–976.
- Kalk, W. W. I., Vissink, A., Spijkervet, F. K. L., Bootsma, H., Kallenberg, C. G. M., & Nieuw Amerongen, A. V. (2001). Sialometry and sialochemistry: Diagnostic tools for Sjögren’s syndrome. *Annals of the Rheumatic Diseases*, 60(12), 1110–1116. <https://doi.org/10.1136/ard.60.12.1110>
- Kalk, W. W. I., Vissink, A., Stegenga, B., Bootsma, H., Nieuw Amerongen, A. V., & Kallenberg, C. G. M. (2002). Sialometry and sialochemistry: A non-invasive approach for diagnosing Sjögren’s syndrome. *Annals of the Rheumatic Diseases*, 61(2), 137–144. <https://doi.org/10.1136/ard.61.2.137>
- Lee, J., Lee, J., Baek, S., Koh, J. H., Kim, J.-W., Kim, S.-Y., Chung, S.-H., Choi, S. S., Cho, M.-L., Kwok, S.-K., Ju, J. H., & Park, S.-H. (2019). Soluble siglec-5 is a novel salivary biomarker for primary Sjögren’s syndrome. *Journal of Autoimmunity*, 100, 114–119. <https://doi.org/10.1016/j.jaut.2019.03.008>
- Lee, Y. J., Scofield, R. H., Hyon, J. Y., Yun, P.-Y., Lee, H.-J., Lee, E. Y., Lee, E. B., & Song, Y. W. (2010). Salivary chemokine levels in patients with primary Sjögren’s syndrome. *Rheumatology*, 49(9), 1747–1752. <https://doi.org/10.1093/rheumatology/keq121>
- Mandel, I. D., & Baurmash, H. (1976). Sialochemistry in Sjögren’s syndrome. *Oral Surgery, Oral Medicine, Oral Pathology*, 41(2), 182–187. [https://doi.org/10.1016/0030-4220\(76\)90229-2](https://doi.org/10.1016/0030-4220(76)90229-2)
- Mandal, S. K., Sandhya, P., Kabeerdoss, J., Ramya, J., Mahasampath, G., & Danda, D. (2018). CXCL13 levels in serum but not in saliva are elevated in Asian Indian patients with primary Sjögren’s syndrome. *Rheumatology International*, 38(5), 831–836. <https://doi.org/10.1007/s00296-018-4006-4>
- Markus, H. M., Otten, H. G., Vroom, T. M., Smeets, T. J. M., Fokkens, N., & Breedveld, F. C. (1993). Rheumatoid factor isotypes in serum and salivary fluid of patients with primary Sjögren’s syndrome. *Clinical Immunology and Immunopathology*, 66(1), 26–32. <https://doi.org/10.1006/clin.1993.1004>
- Martini, D., Gallo, A., Vella, S., Sernissi, F., Cecchetti, A., Luciano, N., Polizzi, E., Conaldi, P. G., Mosca, M., & Baldini, C. (2017). Cystatin S—A candidate biomarker for severity of submandibular gland involvement in Sjögren’s syndrome. *Rheumatology*, 56(6), 1031–1038. <https://doi.org/10.1093/rheumatology/kew501>
- Márton, K., Boros, I., Varga, G., Zelles, T., Fejérdy, P., Zeher, M., & Nagy, G. (2006). Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. *Oral Diseases*, 12(5), 480–486. <https://doi.org/10.1111/j.1601-0825.2005.01224.x>
- Miller, B., Deutsch, O., Redlich, M., Kontinen, Y., Benoliel, R., Zaks, B., Davidovich, E., Palmon, A., & Aframian, D. J. (2012). Sialochemistry and cortisol levels in patients with Sjögren’s syndrome. *Oral Diseases*, 18(3), 255–259. <https://doi.org/10.1111/j.1601-0825.2011.01866.x>
- Moody, M., Zipp, M., & Al-Hashimi, I. (2001). Salivary antispectrin autoantibodies in Sjögren’s syndrome. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, 91(3), 322–327. <https://doi.org/10.1067/moe.2001.112498>
- Ohyama, K., Moriyama, M., Hayashida, J.-N., Tanaka, A., Maehara, T., Ieda, S., Furukawa, S., Ohta, M., Imabayashi, Y., & Nakamura, S. (2015). Saliva as a potential tool for diagnosis of dry mouth including Sjögren’s syndrome. *Oral Diseases*, 21(2), 224–231. <https://doi.org/10.1111/odi.12252>
- Pedersen, A. M. L., Reibel, J., Nordgarden, H., Bergem, H. O., Jensen, J. L., & Nauntofte, B. (1999). Primary Sjögren’s syndrome: Salivary gland function and clinical oral findings. *Oral Diseases*, 5(2), 128–138. <https://doi.org/10.1111/j.1601-0825.1999.tb00077.x>
- Pedersen, A. M. L., Bardow, A., & Nauntofte, B. (2005). Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren’s syndrome. *BMC Clinical Pathology*, 5, 4. <https://doi.org/10.1186/1472-6890-5-4>
- Pijpe, J., Kalk, W. W. I., Bootsma, H., Spijkervet, F. K. L., Kallenberg, C. G. M., & Vissink, A. (2007). Progression of salivary gland dysfunction in patients with Sjögren’s syndrome. *Annals of the Rheumatic Diseases*, 66(1), 107–112. <https://doi.org/10.1136/ard.2006.052647>
- Rusthen, S., Young, A., Herlofson, B. B., Aqrabi, L. A., Rykke, M., Hove, L. H., Palm, Ø., Jensen, J. L., & Singh, P. B. (2017). Oral disorders, saliva secretion, and oral health-related quality of life in patients with primary Sjögren’s syndrome. *European Journal of Oral Sciences*, 125(4), 265–271. <https://doi.org/10.1111/eos.12358>
- Sfriso, P., Ostuni, P. A., Botsios, C., Andretta, M., Oliviero, F., Punzi, L., & Todesco, S. (2003). Serum and salivary neopterin and interferon-γ in primary Sjögren’s syndrome: Correlation with clinical, laboratory and histopathologic features. *Scandinavian Journal of Rheumatology*, 32(2), 74–78. <https://doi.org/10.1080/03009740310000067>
- Singh, P. B., Young, A., Homayouni, A., Hove, L. H., Petrovski, B. E., Herlofson, B. B., Palm, Ø., Rykke, M., & Jensen, J. L. (2019). Distorted taste and impaired oral health in patients with sicca complaints. *Nutrients*, 11(2), 264. <https://doi.org/10.3390/nu11020264>
- Stuchell, R. N., Mandel, I. D., & Baurmash, H. (1984). Clinical utilization of sialochemistry in Sjögren’s syndrome. *Journal of Oral Pathology & Medicine*, 13(3), 303–309. <https://doi.org/10.1111/j.1600-0714.1984.tb01428.x>
- Tishler, M., Yaron, I., Raz, A., Meyer, F. A., & Yaron, M. (1996). Salivary eicosanoid concentration in patients with Sjögren’s

- syndrome. *Annals of the Rheumatic Diseases*, 55(3), 202–204. <https://doi.org/10.1136/ard.55.3.202>
- Tishler, M., Yaron, I., Shirazi, I., & Yaron, M. (1998). Salivary and serum hyaluronic acid concentrations in patients with Sjögren's syndrome. *Annals of the Rheumatic Diseases*, 57(8), 506–508. <https://doi.org/10.1136/ard.57.8.506>
- Tvarijonavičiute, A., Zamora, C., Martínez-Subiela, S., Tecles, F., Pina, F., & Lopez-Jornet, P. (2019). Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren's syndrome: A pilot study. *Clinical Oral Investigations*, 23(3), 1407–1414. <https://doi.org/10.1007/s00784-018-2570-3>
- van Der Geest, S. A., Markusse, H. M., & Swaak, A. J. (1993). Beta2 microglobulin measurements in saliva of patients with primary Sjögren's syndrome: Influence of flow. *Annals of the Rheumatic Diseases*, 52(6), 461–463. <https://doi.org/10.1136/ard.52.6.461>
- van der Reijden, W. A., van der Kwaak, J. S., Veerman, E. C., & Nieuw Amerongen, A. V. (1996). Analysis of the concentration and output of whole salivary constituents in patients with Sjögren's syndrome. *European Journal of Oral Sciences*, 104(4), 335–340. <https://doi.org/10.1111/j.1600-0722.1996.tb00088.x>
- Vissink, A., Kalk, W. W. I., Mansour, K., Spijkervet, F. K. L., Bootsma, H., Roodenburg, J. L. N., Kallenberg, C. G. M., & Amerongen, A. V. N. (2003). Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome. *Archives of Otolaryngology–Head & Neck Surgery*, 129(9), 966–971. <https://doi.org/10.1001/archotol.129.9.966>
- Wang, Z., Li, W., Hong, X., Su, J.-Z., Hua, H., Peng, X., Lv, L., & Yu, G.-Y. (2016). Minor salivary glands function is decreased in hyposalivation-related diseases. *Archives of Oral Biology*, 69, 63–70. <https://doi.org/10.1016/j.archoralbio.2016.05.012>
- Zipp, M. M., Yasbin, L., & Al-Hashimi, I. (1999). The effect of parotid salivary flow rate on the levels of salivary antimicrobial proteins in patients with Sjögren's syndrome. *Quintessence International*, 30(10), 700–705.